

# Utility of current obesity thresholds in signaling diabetes risk in the James Bay Cree of *Eeyou Istchee*

Priya Manjoo,<sup>1</sup> David Dannenbaum,<sup>2,3</sup> Lawrence Joseph,<sup>4</sup> Jill Torrie,<sup>3</sup> Kaberi Dasgupta<sup>4</sup>

**To cite:** Manjoo P, Dannenbaum D, Joseph L, *et al.* Utility of current obesity thresholds in signaling diabetes risk in the James Bay Cree of *Eeyou Istchee*. *BMJ Open Diabetes Research and Care* 2015;**3**: e000114. doi:10.1136/bmjdr-2015-000114

► Additional material is available. To view please visit the journal (<http://dx.doi.org/10.1136/bmjdr-2015-000114>).

Received 3 May 2015  
Revised 14 July 2015  
Accepted 25 July 2015



CrossMark

<sup>1</sup>Department of Medicine, University of Victoria, Victoria, British Columbia, Canada

<sup>2</sup>Department of Family Medicine, McGill University, Montreal, Quebec, Canada

<sup>3</sup>Public Health Department of the Cree Territory, Cree Board of Health & Social Services of James Bay, Chisasibi, Quebec, Canada

<sup>4</sup>Department of Medicine, McGill University, Montreal, Quebec, Canada

**Correspondence to**  
Dr Kaberi Dasgupta;  
[kaberi.dasgupta@mcgill.ca](mailto:kaberi.dasgupta@mcgill.ca)

## ABSTRACT

**Objective:** The anthropometric thresholds signaling type 2 diabetes risk have not been well defined for Aboriginal communities. This study examined current thresholds in terms of ability to capture diabetes risk in the Cree of *Eeyou Istchee* in northern Quebec, Canada.

**Research design and methods:** The study cohort for this analysis included adult participants from the Nituuchischaayihitaa Aschii Multi-Community Environment and Health Study with complete data on anthropometric measures, fasting glucose, and insulin. Diabetes risk was defined as Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) value >2. Positive and negative likelihood ratios (PLR, NLR) of existing obesity thresholds were evaluated (WHO; International Diabetes Federation, IDF; Adult Treatment Panel III, ATP III). Receiver operating curves were examined to estimate optimal thresholds. In a sensitivity analysis, diabetes risk was defined as HOMA-IR >2.7.

**Results:** The WHO 30 kg/m<sup>2</sup> body mass index (BMI) threshold performed well in women (PLR 5.56, 95% CI 1.95 to 15.9; NLR 0.24, 95% CI 0.19 to 0.31) and men (PLR 7.51, 95% CI 2.94 to 19.2; NLR 0.33, 95% CI 0.27 to 0.41). It was close to the estimated optimal threshold (28.5 kg/m<sup>2</sup>). The ATP III waist circumference threshold (102 cm) performed well in men (PLR 4.64, 95% CI 2.47 to 8.71; NLR 0.21, 95% CI 0.16 to 0.28) and was close to the estimated optimal threshold (101 cm). With diabetes risk defined at HOMA-IR >2.7, PLR values were slightly lower with narrower 95% CIs and optimal thresholds were slightly higher; PLR values remained above 3. For other current thresholds, estimated optimal values were higher and none had a PLR above 2.

**Conclusions:** A BMI of 30 kg/m<sup>2</sup> in women and men, and a 102 cm waist circumference in men, are meaningful obesity thresholds in this Aboriginal population. Other thresholds require a further evaluation.

## INTRODUCTION

Worldwide, Aboriginal populations consistently demonstrate high type 2 diabetes risk; a recent review, for example, highlighted a twofold to threefold risk increase in

## Key messages

- Being at or above the WHO obesity body mass index threshold of 30 kg/m<sup>2</sup> or more signals elevated insulin resistance in Cree women and men.
- Being at or above the Adult Treatment Panel III abdominal obesity waist circumference of 102 cm or more signals insulin resistance in Cree men.
- The relevance of other obesity thresholds to insulin resistance in the Cree is not clear.

Australia, New Zealand, and the USA.<sup>1</sup> Obesity is a key driver.<sup>2</sup> The body mass index (BMI, weight in kg/height in m<sup>2</sup>) is the metric most frequently used to capture obesity, defined by the WHO at 30 kg/m<sup>2</sup>.<sup>3</sup> There may, however, be some ethnocultural differences in what constitutes a meaningful BMI threshold. At a given BMI, some studies indicate that Aboriginal groups, Asians, and South Asians, have a greater burden of cardiometabolic risk factors.<sup>4–7</sup> Although not a WHO recommendation, there is some evidence that in Asians, the obesity threshold should be below 27 kg/m<sup>2</sup>.<sup>8</sup> The BMI threshold signaling diabetes risk has not been specifically defined for individual Aboriginal communities or among Aboriginal communities in general.

Similarly, Aboriginal group-specific diabetes risk thresholds have not been defined for other anthropometric measures of obesity, including waist circumference (WC) and waist to hip ratio (WHR). These measures are indicators of abdominal, central, or visceral adiposity. Visceral adipose tissue liberates proinflammatory cytokines such as interleukin 6, tumor necrosis factor  $\alpha$ , free fatty acids and resistin,<sup>9</sup> which promote a state of insulin resistance, a precondition for type 2 diabetes. WC has a closer correlation with visceral adiposity than BMI.<sup>10–12</sup> In the large European Interact study, WC and BMI demonstrated independent associations with diabetes incidence.<sup>13</sup> WHR has also

demonstrated associations with diabetes.<sup>14</sup> Ethnocultural differences have been described for relationships of WC and WHR with cardiometabolic risk factors. For example, South Asian individuals have higher glucose levels than European individuals at an equivalent WC.<sup>15</sup> In a study comparing anthropometric risk factors in terms of ability to predict cardiometabolic risk factors in Aboriginal Australians, WHR demonstrated the greatest predictive power.<sup>16</sup> The International Diabetes Federation (IDF) does specify different visceral adiposity-defining anthropometric thresholds for some ethnocultural groups,<sup>17</sup> but none are specific for Aboriginal populations.

The IDF, WHO, and Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III, ATP III), have defined anthropometric thresholds for obesity. The aim of the present analysis was to evaluate these thresholds in a particular Aboriginal group, in terms of ability to detect individuals at risk for type 2 diabetes.

The group studied was the Cree of the eastern James Bay region (*Eyou Istchee*) in Canada. In this population, diabetes prevalence rose 10-fold from 2.4% in 1983 to 22.1% in 2011 (non-standardized rates). Between the 1940s and 1970s, geographic displacement was imposed to allow natural resource exploitation (eg, forestry, mining, and hydroelectric development). In these Cree communities, there was a shift in food procurement methods from hunting, fishing, and berry picking, until at least the 1970s, to a high intake of processed foods and beverages. A nomadic way of life was supplanted by permanent year-round settlement within nine communities. Snowshoeing and canoeing activities were replaced by snowmobiles and motorboats. As recently documented by the Truth and Reconciliation commission,<sup>18</sup> until 1969, Aboriginal Canadians children were forced to leave their families and attend boarding schools where many were physically, sexually, and psychologically abused; mortality rates were high in what has been described as cultural genocide. All of these factors have likely contributed to the diabetes epidemic faced by Aboriginal communities in Canada.

Insulin resistance, as measured using the Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), signals an increased risk for type 2 diabetes.<sup>19</sup> The present analysis addresses a knowledge gap in the relevance of current anthropometric thresholds for signaling diabetes risk in the James Bay Cree, as captured by elevated HOMA-IR.

## METHODS

### Data sources

Data were collected as part of the Multi-Community Environment and Health (Nituuchischaayihititau Aschii) Study,<sup>20–22</sup> which aimed to provide assessment and surveillance of health status of the Cree in a context of hydroelectric dam projects with potential

environmental impacts. Procedures were approved by Research Ethics Boards of Laval, McGill, and McMaster Universities, and the Cree Board of Health and Social Services of James Bay; community level consent for procedures was obtained through Band Council Resolutions. Individual participants also provided informed consent. Large scale hydroelectric dam projects and concerns about increasing mercury contamination led to the 1986 and 2001 Mercury Agreements between the Grand Council of the Crees (GCC) the government of Quebec, and Hydro-Québec, the government body responsible for dam construction. Part of the agreement included assessment of health impacts (eg, risk of consumption of contaminated fish, risks of avoiding fish consumption). There was a direct planning and consultation process between the Cree Health Board and the Cree communities for a comprehensive environment, and health study with the Mercury Agreement funds.

Simple random sampling without replacement was performed within each age stratum in order to build a list of participants who were then contacted by local recruiters. The overall participation rate (adults and children) was 48%. Demographic variables, and items relating to lifestyle factors and medical histories, were obtained through interviewer-administered questionnaires in either *liyiyiyimuwin* or English. Medical chart reviews were conducted to obtain additional medical history and details of medication use.

Weight was measured on a beam scale and height to the nearest cm. WC to the nearest 0.5 cm was determined at the end of exhalation using a measuring tape horizontally placed between the last floating rib and the iliac crest. Hip circumference to the nearest 0.5 cm was assessed at the level of the pubic symphysis and the point of greatest posterior extension of the buttocks. Blood pressure was assessed following a 5 min rest period, using mercury sphygmomanometers and appropriately sized cuffs, in accordance with Canadian Hypertension Education Program (CHEP) guidelines. Three measurements were taken, and the final two systolic and diastolic measurements were separately averaged. Following an overnight fast, venous blood was sampled for measurements of glucose (spectrophotometric assay, Vitros 950, Vitros Chemistry, Ortho-Clinical Diagnostics, Rochester, New York, USA), insulin (immunoassay with chemiluminescent detection, Bayer Health Care, Advia Centaur), and total cholesterol, high-density lipoprotein (HDL) and triglycerides (Vitros 950 Chemistry Station, Ortho-Clinical Diagnostics, Raritan, New Jersey, USA). Low-density lipoprotein (LDL) was computed. Some participants additionally underwent an oral glucose tolerance test (OGTT, 75 g oral glucose load).

### Cohort for present analysis

We retained adults ( $\geq 18$  years) with data on all three anthropometric parameters (BMI, WC, WHR), and

fasting glucose and insulin measurement, permitting computation of HOMA-IR. We excluded individuals with type 1 diabetes and those without a medical chart review. Medical chart review procedures were implemented only after data collection in two of the nine communities had been completed; these two communities were thus not included in the present analysis.

### Statistical analyses

Statistical analyses were conducted using R (R V.3.0.2. (Copyright (C) 2013 The R Foundation for Statistical Computing). BMI was calculated by dividing the weight (kg) by the squared height (m<sup>2</sup>). WHR was calculated by dividing the WC (cm) by the hip circumference (cm).

The  $\beta$  cell function was estimated using  $\text{HOMA-}\beta = ((20 \times \text{insulin}) / (\text{glucose} - 3.5))\%$ . We computed the HOMA-IR (fasting insulin ( $\mu\text{units/mL}$ )  $\times$  fasting glucose (mmol/L) / 22.5). The constant 22.5 is derived from the product of normal plasma insulin of 5  $\mu\text{units/mL}$  and normal plasma glucose of 4.5 mmol/L.<sup>23 24</sup> Thus, for an individual who has a plasma insulin of 5  $\mu\text{units/mL}$  and glucose of 4.5 mmol/L, HOMA-IR would be 1. While HOMA-IR is a continuous measure of insulin resistance, in the present analyses, 'high' insulin resistance was defined as having an HOMA-IR value greater than 2. To confirm that an HOMA-IR of 2 is of clinical importance in the Cree, we examined the odds of dysglycemia (prediabetes or diabetes) at different HOMA-IR thresholds through age-adjusted logistic regression analyses. In a sensitivity analysis, we defined 'high' insulin resistance as having an HOMA-IR greater than 2.7. A review of HOMA-IR cut-offs used to signal insulin resistance identified 10 studies, with 5 using a value close to 2, and 3 studies using a value of roughly 2.7.<sup>25</sup>

Participants were classified as having type 2 diabetes, prediabetes, or neither condition, based on chart review, use of medication, glucose levels and, when available, OGTT results. Diabetes was defined as having a fasting blood glucose of  $\geq 7.0$  mmol/L and/or by use of antihyperglycemic medication. Prediabetes was defined with either impaired fasting glucose (6.1 to 6.9 mmol/L) or impaired glucose tolerance (7.8 to 11 mmol/L 2 h after ingesting 75 g of glucose solution orally).<sup>26</sup> Descriptive analyses included computation of mean values with SDs or numbers and proportions, as appropriate, stratified by HOMA-IR categories (<2, 2–3, 3–4, >4), separately for women and men. We compared adults retained versus excluded, in terms of the variables available.

We then assessed the test properties of existing obesity and overweight thresholds (men and women separately) in terms of identifying HOMA-IR >2. Thresholds examined included WHO criteria for obesity (BMI  $\geq 30$  kg/m<sup>2</sup>) and overweight (BMI  $\geq 25$  kg/m<sup>2</sup>), and ATP III, IDF (WC  $\geq 80$  cm for Asian women and  $\geq 88$  cm for European women;  $\geq 90$  cm for Asian men and  $\geq 102$  for European men), and WHO criteria (WHR >0.85 for women and >0.90 for men) for abdominal obesity. Test properties included sensitivity (test positive/true positive  $\times 100$ ; ie,

number above the obesity or overweight-defining threshold being examined *divided by* number with HOMA-IR >2, *all multiplied by* 100), specificity (test negative/true negative  $\times 100$ ; ie, number below the obesity or overweight-defining threshold being examined *divided by* number with HOMA-IR <2, *all multiplied by* 100), positive likelihood ratio, PLR (sensitivity / (1–specificity)), and negative likelihood ratio, NLR ((1–sensitivity) / specificity). These were computed with 95% CIs.


In general, shifts from pretest to post-test probability are large with PLRs above 10, moderate between 5 and 10, and small but sometimes clinically important between 2 and 5.<sup>27</sup> Similarly, shifts from pretest to post-test probability are large with NLR values below 0.1, moderate between 0.1 and 0.2, and small but sometimes important between 0.2 and 0.5.<sup>27</sup> These principles were applied in our interpretation of likelihood ratios.

Receiver operating characteristic (ROC) curve<sup>28 29</sup> analyses were used to identify the BMI, WC and WHR thresholds associated with the best possible combination of sensitivity and specificity for HOMA IR >2 in the data set (ie, value in the upper left corner of the ROC). PLR and NLR were computed for the optimal thresholds thus defined.

### RESULTS

There are nearly 10 000 adults living in Eeyou Istchee. A total of 1405 individuals were consented for data collection procedures, which included medical chart review (figure 1). This included 860 adults. Among these adults, 16 did not have WC data, 53 did not have a chart review, 2 had type 1 diabetes, and in 6, prediabetes/diabetes status was not clear from the data available. Seven hundred and eighty-three adults were retained in the present analyses (783/860, 91%). In adults excluded, mean HOMA-IR was >6 both in women and in men, and characteristics (results not shown) were similar to those in the upper two HOMA-IR categories of those retained (ie, study cohort, table 1).

The prevalence of diabetes was 12.4% (57) in men and 12.7% (41) in women. The prevalence of prediabetes was 19.4% (63) in men and 24.8% (114) in women. In the study cohort, HOMA-IR distributions in women and men had a right skew, but even among those without diabetes or prediabetes, the mean HOMA-IR was high (5 in women and 4 in men; see online supplementary figure S1A, B). The odds of prediabetes dysglycemia increased twofold above an HOMA-IR threshold of 2, both in age-adjusted and in unadjusted logistic regression analyses (see online supplementary table S1). While mean HOMA-IR was high in women and men, a lower proportion of women had HOMA-IR value of under 2 (4.6% of women, 1; 13.8% of men, table 1). HOMA-IR was higher in older individuals and there was a step-wise increase in all obesity and blood pressure measures, and in medication use, across HOMA-IR categories. While total cholesterol to



**Figure 1** Participant flow.

HDL ratio and LDL-C differed little across groups, HDL was lower and triglycerides higher in the upper two HOMA-IR categories. HOMA- $\beta$  increased with HOMA-IR.

### Body mass index

In women, the WHO BMI obesity threshold of  $30 \text{ kg/m}^2$  had a sensitivity of 79% (95% CI 75% to 83%) and specificity of 86% (95% CI 64% to 97%) for HOMA-IR  $>2$  (table 2). The PLR was 5.56 (95% CI 1.95 to 15.9) and NLR was 0.24 (95% CI 0.19 to 0.31). In men, this threshold performed similarly with a sensitivity of 70% (95% CI 64% to 75%) and a specificity of 91% (95% CI 78% to 97%), PLR of 7.51 (95% CI 2.94 to 19.2), and NLR of 0.33 (95% CI 0.27 to 0.41). The WHO BMI overweight threshold of  $25 \text{ kg/m}^2$  had a higher sensitivity but lower specificity, and lower PLR. The threshold with the maximum sensitivity and specificity (ROC analysis; see online supplementary figure S2A, B) was  $28.5 \text{ kg/m}^2$ . Defining insulin resistance at HOMA-IR  $>2.7$  instead of at

2, resulted in a higher sensitivity and lower specificity for the obesity threshold of  $30 \text{ kg/m}^2$  (see online supplementary table S2); PLR values remained above 3 both in women and in men. The optimal threshold rose to  $30.8 \text{ kg/m}^2$  in women and  $29.8 \text{ kg/m}^2$  in men.

### Waist circumference

In women, a WC of 80 cm (ATP III and IDF/Asian) and 88 cm (IDF/European) were both highly sensitive but had low specificities and PLRs, and higher NLRs (table 2); PLR values were also low when the HOMA-IR threshold was raised to 2.7 (see online supplementary table S2). The optimal ROC-defined threshold (see online supplementary figure S2C) was higher at 98 cm (sensitivity of 87% (95% CI 83% to 90%), specificity of 81% (95% CI 58% to 95%), PLR of 4.55 (95% CI 1.88 to 11.0), and NLR of 0.16 (95% CI 0.12 to 0.23)). With an HOMA-IR threshold of 2.7, the optimal WC threshold in women was 105.5 cm (see online supplementary table S2).

In men, a WC of 94 cm (IDF/European) and 90 cm (IDF/Asian men) both had high sensitivity but low specificity (table 2). A WC of 102 cm (ATPIII) had a better balance between sensitivity (82%, 95% CI 77% to 87%) and specificity (82%, 95% CI 68% to 92%), with a PLR of 4.64 (95% CI 2.47 to 8.71) and NLR of 0.21 (95% CI 0.16 to 0.28). With an HOMA-IR threshold of 2.7, a WC of 102 cm or more in men had a PLR of 2.61 and NLR of 0.17. The optimal ROC-defined threshold for WC in men was very similar to the ATP III threshold at 101 cm (see online supplementary figure S2D). With an HOMA-IR threshold of 2.7, the optimal threshold was higher at 105.5 cm.

### Waist to hip ratio

In women (table 2), the WHO 0.85 threshold was sensitive (92%, 95% CI 89% to 95%) and moderately specific (48%, 95% CI 26% to 70%) with a PLR of 1.76 (95% CI 1.17% to 2.65%) and an NLR of 0.16 (95% CI 0.09% to 0.29%) (table 2), similar to the test characteristics of the WHO 0.90 threshold in men. PLR values were also below 2 with an HOMA-IR threshold of 2.7. The optimal ROC-defined threshold for WHR in women was 0.87 (see online supplementary figure S2E) and the optimal value in men was 0.98 (see online supplementary figure S2F). In women, the optimal ROC-defined threshold had a slightly lower sensitivity (87%, 95% CI 83% to 90%) but much higher specificity (81%, 95% CI 58% to 95%) and PLR (4.55, 95% CI 1.88, 11.0); NLR was 0.16 (95% CI 0.12 to 0.23). In men, the optimal ROC-defined threshold also had a lower sensitivity (65%, 95% CI 59% to 70%) and higher specificity (84%, 95% CI 71% to 94%) and PLR (4.17, 95% CI 2.10 to 8.28); NLR was 0.42 (95% CI 0.34 to 0.51). With an HOMA-IR threshold of 2.7, PLR values were also below 2 both in women and in men; the optimal WHR was 0.95 in women and remained at 0.98 in men.



**Table 1** Characteristics, by degree of hepatic insulin resistance, in women and men

	Women				Men			
	HOMA-IR <2 N=21	HOMA-IR 2–3 N=50	HOMA IR 3–4 N=65	HOMA IR >4 N=322	HOMA IR <2 N=45	HOMA-IR 2–3 N=55	HOMA-IR 3–4 N=48	HOMA-IR >4 N=176
Age, years, mean (SD)	37 (18)	36.5 (16.3)	36.4 (14.3)	39.7 (14.9)	32 (16)	38 (15)	37 (14.8)	45 (16.2)
Tobacco use, N (%)	13 (62)	34 (68)	42 (64)	152 (47)	27 (62)	31 (56)	27 (56)	69 (39)
Anthropometric measures								
BMI, kg/m <sup>2</sup> , mean (SD)	25.1 (4.4)	29.2 (5.3)	32.7 (5.6)	37.4 (6.8)	24.8 (3.3)	28.9 (3.5)	31.3 (4.1)	34.6 (5.5)
Waist circumference, cm, mean (SD)	89.4 (12.8)	99.6 (12.5)	106.2 (12.6)	117.3 (13.9)	93.9 (11.1)	102.5 (9.9)	107.3 (14.3)	117.8 (14.1)
Hip circumference, cm, mean (SD)	102.7 (9.1)	108.2 (11)	114.3 (10.1)	122.1 (13.1)	102.3 (7.1)	108 (6.3)	109.6 (10.7)	114.7 (10.3)
WHR, mean (SD)	0.87 (0.07)	0.92 (0.07)	0.91 (0.13)	0.96 (0.07)	0.91 (0.07)	0.95 (0.06)	0.98 (0.06)	1.03 (0.06)
Glycemia and insulin resistance								
Fasting glucose, mmol/L, mean (SD)	4.6 (0.5)	5.1 (0.4)	5.2 (0.6)	7.0 (2.3)	4.9 (0.4)	5.3 (0.4)	5.5 (0.7)	6.9 (2.8)
Fasting insulin, $\mu$ U/mL, mean (SD)	7.9 (1.7)	11.6 (1.5)	15.4 (2.4)	31.7 (18.9)	7.4 (1.3)	10.5 (1.3)	14.4 (2.0)	31.1 (20)
HOMA-IR, mean (SD)	1.6 (0.3)	2.6 (0.3)	3.5 (0.3)	10.2 (10.4)	1.6 (0.3)	2.4 (0.7)	3.5 (0.3)	9.5 (7.6)
HOMA-B, mean (SD)	155 (109)	162 (75)	215 (137)	255 (157)	118 (47)	127 (43)	163.4 (76)	240 (158)
Lipids								
Total cholesterol, mmol/L, mean (SD)	4.9 (1.2)	4.4 (0.9)	4.6 (0.8)	4.4 (0.9)	4.5 (0.9)	4.9 (0.9)	4.9 (0.8)	4.8 (1.0)
LDL-C, mmol/L, mean (SD)	2.7 (0.9)	2.4 (0.7)	2.6 (0.6)	2.4 (0.7)	2.6 (0.8)	3.0 (0.8)	3.0 (0.8)	2.8 (0.8)
HDL-C, mmol/L, mean (SD)	1.6 (0.5)	1.6 (0.4)	1.3 (0.3)	1.2 (0.3)	1.4 (0.4)	1.3 (0.3)	1.2 (0.2)	1.1 (0.2)
Triglycerides, mmol/L, mean (SD)	1.3 (1.1)	1.0 (0.4)	1.3 (0.5)	1.7 (0.9)	1.0 (0.4)	1.3 (0.7)	1.5 (0.6)	2.0 (1.8)
Cholesterol-HDL ratio, mean (SD)	3.3 (1.7)	2.9 (0.7)	3.5 (0.7)	3.8 (1.0)	3.3 (1.0)	4.0 (9.8)	4.2 (1.0)	4.5 (1.9)
Blood pressure								
Systolic, mm Hg, mean (SD)	109 (15)	114 (13)	119 (14)	120 (15)	115 (9)	121 (11)	125 (13)	128 (15)
Diastolic, mm Hg, mean (SD)	67 (10)	70 (11)	72 (11)	73 (11)	71 (9)	75 (10)	76 (10)	78 (10)
Medication Use								
Antihypertensive, N (%)	0 (0)	6 (12)	12 (18)	110 (34)	3 (7)	8 (14)	9 (19)	67 (38)
Lipid-lowering, N (%)	0 (0)	2 (4)	2 (3)	51 (15)	1 (2)	1 (2)	5 (10)	36 (20)
Oral antihyperglycemic, N (%)	0 (0)	2 (4)	6 (9)	82 (25)	0 (0)	0 (0)	6 (12)	37 (21)
Insulin, N (%)	0 (0)	0 (0)	0 (0)	34 (11)	0 (0)	0 (0)	0 (0)	8 (5)

BMI, body mass index; HDL, high-density lipoprotein; HOMA-IR, Homeostatic Model Assessment-Insulin resistance computed as (fasting serum insulin ( $\mu$ U/mL) $\times$  fasting plasma glucose (mmol/L))/22.5; HOMA-B, Homeostatic Model Assessment computed as (20 $\times$ fasting serum insulin ( $\mu$ U/mL))/(glucose (mmol/L)—3.5); LDL, low-density lipoprotein; WHR, waist-to-hip ratio.

Table 2 Properties of obesity thresholds for detection of HOMA-IR &gt;2 among Cree

	BMI thresholds			Waist circumference thresholds				Waist to hip ratio thresholds		
	WHO threshold for obesity, $\geq 30$ kg/m <sup>2</sup>	WHO threshold for overweight, $\geq 25$ kg/m <sup>2</sup>	ROC-derived threshold, $\geq 28.5$ kg/m <sup>2</sup>	ATP III thresholds for abdominal obesity		IDF thresholds for abdominal obesity		ROC-derived threshold	WHO	ROC-derived threshold
				Asian	European	Asian	European			
Women	79 (75 to 83)	96 (94 to 98)	87 (84 to 90)	$\geq 88$ cm	$\geq 80$ cm	$\geq 80$ cm	$\geq 98$ cm	0.85	0.87	
Sensitivity, % (95% CI)				97 (96 to 99)	99 (98 to 1.00)	99 (98 to 100)	87 (83 to 90)	92 (89 to 95)	87 (83 to 90)	
Specificity, % (95% CI)	86 (64 to 97)	52 (30 to 74)	86 (64 to 97)	48 (26 to 70)	29 (11 to 52)	29 (11 to 52)	81 (58 to 95)	48 (26 to 70)	81 (58 to 95)	
Positive likelihood ratio (95% CI)	5.56 (1.95 to 15.9)	2.01 (1.28 to 3.15)	6.11 (2.14 to 17.4)	1.86 (1.24 to 2.80)	1.39 (1.06 to 1.82)	1.39 (1.06 to 1.82)	4.55 (1.88 to 11.0)	1.76 (1.17 to 2.65)	4.55 (1.88 to 11.0)	
Negative likelihood ratio (95% CI)	0.24 (0.19 to 0.31)	0.08 (0.04 to 0.15)	0.15 (0.11 to 0.20)	0.05 (0.03 to 0.11)	0.02 (0.01 to 0.09)	0.02 (0.01 to 0.09)	0.16 (0.12 to 0.23)	0.16 (0.09 to 0.29)	0.16 (0.12 to 0.23)	
Men	70 (64 to 75)	95 (92 to 97)	81 (76 to 86)	$\geq 102$ cm	$\geq 90$ cm	$\geq 94$ cm	$\geq 101$ cm	0.90	0.98	
Sensitivity, % (95% CI)				82 (77 to 87)	97 (94 to 99)	94 (90 to 96)	85 (81 to 89)	94 (90 to 96)	65 (59 to 70)	
Specificity, % (95% CI)	91 (78 to 97)	47 (33 to 61)	88 (75 to 96)	82 (68 to 92)	36 (22 to 51)	47 (32 to 62)	80 (65 to 90)	42 (28 to 58)	84 (71 to 94)	
Positive likelihood ratio (95% CI)	7.51 (2.94 to 19.16)	1.80 (1.40 to 2.33)	6.99 (3.06 to 15.96)	4.64 (2.47 to 8.71)	1.50 (1.21 to 1.87)	1.75 (1.33 to 2.31)	4.27 (2.37 to 7.67)	1.62 (1.26 to 2.08)	4.17 (2.10 to 8.28)	
Negative likelihood ratio (95% CI)	0.33 (0.27 to 0.41)	0.10 (0.06 to 0.19)	0.21 (0.16 to 0.28)	0.21 (0.16 to 0.28)	0.09 (0.04 to 0.19)	0.14 (0.08 to 0.24)	0.18 (0.13 to 0.25)	0.15 (0.09 to 0.27)	0.42 (0.34 to 0.51)	

ATP III, Adult Treatment Panel III; BMI, body mass index; HOMA-IR, Homeostatic Model Assessment-Insulin resistance computed as fasting serum insulin ( $\mu$ U/mL) $\times$  fasting plasma glucose (mmol/L-1)/22.5; IDF, International Diabetes Federation; ROC, receiver operating curve.

## DISCUSSION

Our analyses indicate that among the Cree, an HOMA-IR >2 is consistent with a twofold greater odds of type 2 diabetes. Compared against this risk indicator, the current WHO 30 kg/m<sup>2</sup> BMI threshold demonstrated moderately important PLR values (ie, above 5) and somewhat important NLR values (ie, 0.2 to 0.5) in women (PLR 5.56, 95% CI 1.95 to 15.9; NLR 0.24, 95% CI 0.19 to 0.31) and men (PLR 7.51, 95% CI 2.94 to 19.2; NLR 0.33, 95% CI 0.27 to 0.41). The optimal value was slightly lower (28.5 kg/m<sup>2</sup>) than the WHO threshold. In men, the ATP III WC threshold (102 cm) had a PLR close to 5 (PLR 4.64, 95% CI 2.47 to 8.71; NLR 0.21, 95% CI 0.16 to 0.28). For WC in women, and WHR in women and men, none of the current thresholds had a PLR value above 5. The findings indicate that for diabetes risk assessment in the Cree, a BMI of above 30 kg/m<sup>2</sup> is a risk factor to consider. In men, a WC >102 cm may also be a meaningful threshold in terms of diabetes risk. These thresholds also appeared reasonable when the HOMA-IR cut-off was raised from 2 to 2.7 in sensitivity analyses.

The analyses presented suggest that, for WC in women and WHR in women as well as in men, current thresholds are not associated with a high PLR, and our analyses suggest that optimal thresholds may be higher, although this requires confirmation. In a previous Canadian study,<sup>30</sup> Lear and colleagues compared Aboriginal (at least three Aboriginal grandparents) and European-origin Canadians living in Vancouver. They measured anthropometric parameters, blood pressure, and cardio-metabolic risk factors, and performed a single slice abdominal CT scan to assess visceral and subcutaneous adipose tissue. At the same BMI and WC, they identified no difference in subcutaneous or visceral adipose tissue areas between Aboriginal and European participants, nor in the prevalence of dyslipidemia, hypertension, impaired fasting glucose or metabolic syndrome. Insulin levels, however, were higher in Aboriginal Canadians, and thus HOMA-IR values, had they been computed, would likely have been higher at a given WC or BMI. It is thus possible that at-risk WC, BMI, and WHR levels, may differ between Aboriginal populations. Similarly, another previous Canadian study<sup>7</sup> used factor analysis to ascertain the BMI cut-points equivalent to 30 kg/m<sup>2</sup> in South Asian, Chinese, and Aboriginal Canadians (Six Nations, Ontario). Their analysis suggested that a much lower BMI was optimal in these groups (ie, <22 kg/m<sup>2</sup>) including the Aboriginal Canadians studied. They included a mix of Aboriginal Canadians of Mohawk, Cayuga, Onondaga, Oneida, Seneca and Tuscarora origin, living in the Six Nations community in Ontario; they did not include the Cree. In contrast, we determined the BMI cut-point of 30 kg/m<sup>2</sup> to be applicable in terms of risk of elevated HOMA-IR in the James Bay Cree. There is a need for population-specific thresholds to define high risk in groups that may have important cultural, genetic, and epigenetic differences.

Our analyses are limited by their cross-sectional nature; in an ideal study, potential thresholds would be examined in terms of ability to predict the development of prediabetes and diabetes. Given the limitations of the available data, we opted to use an HOMA-IR above 2 as the diabetes risk indicator against which current obesity thresholds were evaluated, and performed a sensitivity analysis using an HOMA-IR of above 2.7. Although the HOMA IR has been extensively tested against other measures of insulin resistance,<sup>31 32</sup> it is a surrogate marker, and there may be differences between the assays used to derive the HOMA IR equation and the assays of insulin resistance used in our study. However, at the HOMA-IR of >2, there is a clinically important increase in odds of prediabetes or diabetes, as confirmed by our logistic regression analyses (see online supplementary table S1).

## CONCLUSIONS

Identifying participants at the stage of insulin resistance before the development of diabetes is an important window of opportunity for focused intensive lifestyle change efforts, demonstrated to be effective in large clinical trials.<sup>33–36</sup> Anecdotally, clinicians working in Eeyou Istchee (Cree territory) have reported to us that, given the high frequency of a BMI above 30 kg/m<sup>2</sup> among their patients, they have started questioning what is 'normal' in the community, and considered the possibility that a BMI above this threshold might not have the same importance here as it has in the general population. The analyses presented do suggest that Cree women may be able to tolerate a WC above current thresholds before experiencing an important increase in insulin resistance. This remains to be confirmed in longitudinal studies. A large majority of Cree in Eeyou Istchee have a BMI above 30 kg/m<sup>2</sup>. Our findings indicate that in this Aboriginal population, a BMI above 30 kg/m<sup>2</sup> is associated with a high HOMA-IR. Further, a BMI at this level has a moderately high PLR value for HOMA-IR >2 in women and men. Thus, the WHO obesity threshold demonstrates clinical importance in this regard for this population.

**Acknowledgements** The authors thank the Principal Investigators of the Multi-Community Environment and Health Longitudinal (Nituuchischaayihitaaui Aschii) Study and the Cree Board of Health and Social Services of James Bay for permitting this data analysis.

**Contributors** PM, DD, and KD formulated the study question and devised the analytic plan. PM and KD performed the literature search and summarized the literature. PM performed the data-analysis in collaboration with LJ and KD. PM and KD co-wrote the manuscript, with review and comment by DD, LJ, and JT. KD is the guarantor and, as such, had full access to all the data in the study, and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Funding** Data collection for the original study (Nituuchischaayihitaaui Aschii: Multi-Community Environment-and-Health Study in Iiyiyuu Aschii) was funded through an agreement between the Grand Council of the Cree and Hydro Quebec; it was supported by the Cree people of northern Québec, the Cree First Nations and the Cree Board of Health and Social Services of James Bay, through financial contributions from Niskamoon Corporation.

**Competing interests** PM is the assistant professor of Department of Medicine at the University of British Columbia. DD is the assistant professor of Department of Medicine at McGill University and the medical advisor for chronic diseases with the Cree Board of Health and Social Services of James Bay. LJ is the professor of Department of Epidemiology, Biostatistics, and Occupational Health at McGill University. JT is the assistant director of Public Health Surveillance, Evaluation, Research, and Communication, and Clinical Preventive Practices with the Cree Board of Health and Social Services of James Bay. KD is the associate professor in the Department of Medicine of McGill University and holds a Senior Investigator award from the Fonds de Recherche en santé du Québec.

**Ethics approval** The procedures were approved by Research Ethics Boards of Laval, McGill, and McMaster Universities, and from Board resolution of the Cree Board of Health and Social Services of James Bay; community level consent for the study was obtained through Band Council Resolutions.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Data sharing statement** The data are owned by the Cree people of northern Québec and the Cree First Nations, and are held by the Cree Board of Health and Social Services of James Bay. Permission to use these data must be sought from the owners of the data.

**Open Access** This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

## REFERENCES

1. Lucero AA, Lambrick DM, Faulkner JA, *et al.* Modifiable cardiovascular disease risk factors among indigenous populations. *Adv Prev Med* 2014;2014:547018.
2. Sui X, Hooker SP, Lee IM, *et al.* A prospective study of cardiorespiratory fitness and risk of type 2 diabetes in women. *Diabetes Care* 2008;31:550–5.
3. [No authors listed]. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. *World Health Organ Tech Rep Ser* 1995;854:1–452.
4. Lear SA, Toma M, Birmingham CL, *et al.* Modification of the relationship between simple anthropometric indices and risk factors by ethnic background. *Metabolism* 2003;52:1295–301.
5. Lear SA, Chen MM, Frohlich JJ, *et al.* The relationship between waist circumference and metabolic risk factors: cohorts of European and Chinese descent. *Metabolism* 2002;51:1427–32.
6. Razak F, Anand S, Vuksan V, *et al.* Ethnic differences in the relationships between obesity and glucose-metabolic abnormalities: a cross-sectional population-based study. *Int J Obes (Lond)* 2005;29:656–67.
7. Razak F, Anand SS, Shannon H, *et al.* Defining obesity cut points in a multiethnic population. *Circulation* 2007;115:2111–18.
8. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. *Lancet* 2004;363:157–63.
9. Jensen MD. Adipose tissue and fatty acid metabolism in humans. *J R Soc Med* 2002;95(Suppl 42):3–7.
10. Pouliot MC, Despres JP, Lemieux S, *et al.* Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. *Am J Cardiol* 1994;73:460–8.
11. Han TS, van Leer EM, Seidell JC, *et al.* Waist circumference action levels in the identification of cardiovascular risk factors: prevalence study in a random sample. *BMJ* 1995;311:1401–5.
12. Lean ME, Han TS, Morrison CE. Waist circumference as a measure for indicating need for weight management. *BMJ* 1995;311:158–61.
13. Langenberg C, Sharp SJ, Schulze MB, *et al.* Long-term risk of incident type 2 diabetes and measures of overall and regional obesity: the EPIC-InterAct case-cohort study. *PLoS Med* 2012;9:e1001230.
14. Qiao Q, Nyamdorj R. The optimal cutoff values and their performance of waist circumference and waist-to-hip ratio for diagnosing type II diabetes. *Eur J Clin Nutr* 2010;64:23–9.
15. Bodicoat DH, Gray LJ, Henson J, *et al.* Body mass index and waist circumference cut-points in multi-ethnic populations from the UK and

- India: the ADDITION-Leicester, Jaipur heart watch and New Delhi cross-sectional studies. *PLoS ONE* 2014;9:e90813.
16. Li M, McDermott RA. Using anthropometric indices to predict cardio-metabolic risk factors in Australian indigenous populations. *Diabetes Res Clin Pract* 2010;87:401–6.
  17. The IDF consensus worldwide definition of the metabolic syndrome. [article online]. 2006.
  18. Commission of Canada. Truth and Reconciliation. 2015.
  19. Gast KB, Tjeerdema N, Stijnen T, *et al.* Insulin resistance and risk of incident cardiovascular events in adults without diabetes: meta-analysis. *PLoS ONE* 2012;7:e52036.
  20. Egeland GM, Denomme D, Lejeune P, *et al.* Concurrent validity of the International Physical Activity Questionnaire (IPAQ) in an Iiyiyiu Aschii (Cree) community. *Can J Public Health* 2008;99:307–10.
  21. Johnson-Down L, Labonte ME, Martin ID, *et al.* Quality of diet is associated with insulin resistance in the Cree (Eeyouch) indigenous population of northern Quebec. *Nutr Metab Cardiovasc Dis* 2015;25:85–92.
  22. Johnson-Down LM, Egeland GM. How is nutrition transition affecting dietary adequacy in Eeyouch (Cree) adults of Northern Quebec, Canada? *Appl Physiol Nutr Metab* 2013;38:300–5.
  23. Albareda M, Rodriguez-Espinosa J, Murugo M, *et al.* Assessment of insulin sensitivity and beta-cell function from measurements in the fasting state and during an oral glucose tolerance test. *Diabetologia* 2000;43:1507–11.
  24. Bonora E, Formentini G, Calcaterra F, *et al.* HOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. *Diabetes Care* 2002;25:1135–41.
  25. Gayoso-Diz P, Otero-González A, Rodríguez-Alvarez MX, *et al.* Insulin resistance (HOMA-IR) cut-off values and the metabolic syndrome in a general adult population: effect of gender and age: EPIRCE cross-sectional study. *BMC Endocr Disord* 2013;13:47.
  26. Goldenberg R, Punthakee Z. Definition, classification and diagnosis of diabetes, prediabetes and metabolic syndrome. *Can J Diabetes* 2013;37(Suppl 1):S8–11.
  27. Guyatt G, Rennie D, Meade M, *et al.* *Users' guides to the medical literature: a manual for evidence-based clinical practice*. 2nd edn. McGraw-Hill Professional, 2008.
  28. Metz CE. Basic principles of ROC analysis. *Semin Nucl Med* 1978;8:283–98.
  29. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. *Clin Chem* 1993;39:561–77.
  30. Lear SA, Humphries KH, Frohlich JJ, *et al.* Appropriateness of current thresholds for obesity-related measures among Aboriginal people. *CMAJ* 2007;177:1499–505.
  31. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. *Diabetes Care* 2004;27:1487–95.
  32. Hermans MP, Levy JC, Morris RJ, *et al.* Comparison of insulin sensitivity tests across a range of glucose tolerance from normal to diabetes. *Diabetologia* 1999;42:678–87.
  33. Tuomilehto J, Lindström J, Eriksson J, *et al.* for the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 2001;344:1343–50.
  34. Knowler W, Barrett-Connor E, Fowler S, *et al.* Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 2002;346:393–403.
  35. Ramachandran A, Snehalatha C, Mary S, *et al.* The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). *Diabetologia* 2006;49:289–97.
  36. Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. *Diabetes Res Clin Pract* 2005;67:152–62.